As used in this Form 10-K, “we,” “us,” “our,” and “the Company” refer to Insys Therapeutics Inc. and our subsidiaries. We are a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. We have two marketed products: SUBSYS®, a proprietary sublingual fentanyl spray indicated for the management of BTCP patients 18 years of age and older who are already receiving and are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain; and SYNDROS®, a proprietary, orally administered liquid formulation of dronabinol for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments and anorexia associated with weight loss in patients with AIDS. As discussed below, on November 5, 2018, we announced a process to review strategic alternatives for our opioid-related assets including SUBSYS®. The Company has also engaged Lazard Freres & Co. LLC to advise the Company on capital planning and the evaluation of strategic alternatives. Additional potential transactions that we may consider include a variety of different business arrangements including spin-offs, strategic licensing and partnerships, joint ventures, restructurings, divestitures, business combinations and investments.
Company profile
Ticker
INSY, INSYQ
Exchange
Website
CEO
Andrew G. Long
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
510327886
Latest filings (excl ownership)
15-12B
Securities registration termination
11 Feb 20
8-K
Other Events
11 Feb 20
8-K
Monthly Operating Report
10 Feb 20
8-K
Entry into a Material Definitive Agreement
5 Feb 20
8-K
Regulation FD Disclosure
17 Jan 20
8-K
Regulation FD Disclosure
10 Jan 20
8-K
Entry into a Material Definitive Agreement
6 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jan 20
Latest ownership filings
SC 13G
Insys Therapeutics, Inc.
19 Nov 19
4
Andrece Housley
6 Jun 19
3
Andrece Housley
6 Jun 19
4
Andrew G Long
5 Jun 19
SC 13G/A
Insys Therapeutics, Inc.
29 Apr 19
4
ELIZABETH BOHLEN
23 Apr 19
4
Vaseem Mahboob
23 Apr 19
4
Mark E Nance
23 Apr 19
4
Geertrui Vanhove
23 Apr 19
3
Geertrui Vanhove
23 Apr 19
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|